Antithrombotic Therapy in Peripheral Arterial Disease

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 289-298

  Lipsitz, Evan C ^a   Kim, Soo ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIVITAMIN K; C REACTIVE PROTEIN; CILOSTAZOL; CLOPIDOGREL; DILTIAZEM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OMEPRAZOLE; PENTOXIFYLLINE; TICLOPIDINE; UROKINASE;

AGED; ANGIOPLASTY; ANKLE BRACHIAL INDEX; ANTICOAGULANT THERAPY; ARTERY DISEASE; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; BLOOD TOXICITY; CLAUDICATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DIABETES MELLITUS; DIARRHEA; DIZZINESS; FIBRINOLYTIC THERAPY; GRAPEFRUIT JUICE; HEADACHE; HEART PALPITATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; LIFESTYLE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; THROMBOCYTE AGGREGATION;

ANTICOAGULANTS; ASPIRIN; ATHEROSCLEROSIS; COMORBIDITY; DIABETIC ANGIOPATHIES; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; PENTOXIFYLLINE; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; SMOKING; TETRAZOLES; THROMBOLYTIC THERAPY; TICLOPIDINE;

EID: 41749088477     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.004     Document Type: Review

References (55)

1. Criqi M.H., Denenber J.O., Langer R.D., et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 2 (1997) 221-226
2. Murabito J.M., Evans J.C., Nieto K., et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 143 (2002) 961-965
3. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 289 (2003) 2560-2572
4. Radack K., and Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta-analysis of randomized controlled trials. Arch Intern Med 151 (1991) 1769-1776
5. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145
6. Newby D.E., Wright R.A., Labinjoh C., et al. Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation 99 (1999) 1411-1415
7. Ingolfsson I.O., Sigurdsson G., Sigvaldason H., et al. Marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968-1986: a strong relationship to smoking and serum cholesterol-the Reykjavik Study. J Clin Epidemiol 47 (1994) 1237-1243
8. Jonason T., and Bergstrom R. Cessation of smoking in patients with intermittent claudication. Br J Surg 69 (1982) S24
9. Aemli F.M., Stein M., Provan J.L., et al. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 3 (1999) 20-25
10. Morita H., Ikeda H., Haramaki N., et al. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term Smokers. J Am Coll Cardiol 45 (2005) 589-594
11. The Tobacco Use and Dependence Clinical Practice Guideline Panel. Staff, and Consortium Representatives. A clinical practice guideline for treating tobacco use and dependence: a US public health service report. JAMA 283 (2000) 3244-3254
12. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 26 (2003) 3333-3341
13. Newman A.B., Siscovick D.S., Manolio T.A., et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 88 (1993) 837-845
14. The Diabetes Control and Complications Trial Investigators. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75 (1995) 894-903
15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
16. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. Diabetes Control and Complications Trial; Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 348 (2003) 2294-2303
17. Stoyioglou A., and Jaff M.R. Medical treatment of peripheral arterial disease: a comprehensive review. J Vasc Interv Radiol 15 (2004) 1197-1207
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
19. Mondillo S., Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003) 359-364
20. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
21. Aronow W.S., Nayak D., Woodworth S., et al. Effects of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 92 (2003) 711-712
22. Abbruzzese T.A., Havens J., Belkin M., et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 39 (2004) 1178-1185
23. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1502
24. Ridker C.P., Cannon P.M., Morrow D., et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
25. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 352 (2005) 29-38
26. Bernstein E.F., and Fronek A. Current statues of non-invasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 62 (1982) 473-487
27. McGrae McDermott M., Kerwin D.R., Liu K., et al. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice. J Gen Intern Med 16 (2001) 384
28. Hirsch A.T., Criqui M.H., Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001) 1317
29. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
30. Goldhaber S.Z., Manson J.E., Stampfer M.J., et al. Low-dose aspirin and subsequent peripheral arterial surgery in the Physicians' Health Study. Lancet 3450 (1992) 143-145
31. Clagett G.P., Sobel M., Jackson M.R., et al. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 609S-626S
32. Dormandy J.A., and Rutherford R.B. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 31 (2000) S1-S296
33. Boissel J.P., Peyrieux J.C., and Destors J.M. Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?. Thromb Haemost 62 (1989) 681-685
34. Arcan J.C., and Panak E. Ticlopidine in the treatment of peripheral occlusive arterial disease. Semin Thromb Hemost 15 (1989) 167-170
35. Girolami B., Bernardi E., Prins M.H., et al. Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysis. Thromb Haemost 81 (1999) 715
36. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine: a review of 60 cases. Ann Intern Med 128 (1998) 541-544
37. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348 (1996) 1329-1339
38. Diener H.C., Bogousslavsky J., Brass L.M., et al., MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
39. Angelkort B., Maurin N., and Bouteng K. Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial disease. Curr Med Res Opin 6 (1979) 255-258
40. Johnson W.C., Sentissi J.M., Baldwin D., et al. Treatment of claudication with pentoxifylline: are benefits related to improvement in viscosity?. J Vasc Surg 6 (1987) 211-216
41. Radack K., and Wyderski R.J. Conservative management of intermittent claudication. Ann Intern Med 113 (1990) 135-146
42. Money S.R., Herd J.A., Isaacsohn J.L., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-275
43. Dawson D.L., Cutler B.S., Messiner M.H., et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
44. Dawson D.L., DeMaioribus C.A., Hagino R.T., et al. The effect of withdrawal of drugs treating intermittent claudication. Am J Surg 178 (1999) 141-146
45. Wilhite D., Comerota A.J., Schmieder F.A., et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38 (2003) 710
46. Drugs for intermittent claudication. Med Lett Drugs Ther 46 (2004) 13
47. Cosmi B., Conti E., and Coccheri S. Anticoagulant (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2 (2001) CD001999
48. Lewis B.E., Walenga J.M., and Wallis D.E. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost 23 (1997) 197
49. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity: the STILE trial. Ann Surg 220 (1994) 251-268
50. Schweizer J., Altmann E., Flor J.H., et al. Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions. Eur J Radiol 23 (1996) 64-73
51. Duda S.H., Tepe G., Luz O., et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus urokinase alone: a randomized pilot trial (the PROMPT study). Radiology 221 (2001) 689-696
52. Ouriel K., Kendarpa K., Schuerr D.M., et al. Prourokinase versus urokinase for recanalization of peripheral occlusions, safety and efficacy: the PURPOSE trial. J Vasc Interv Radiol 10 (1999) 1083-1091
53. Weaver F.A., Comerota A.J., Youngblood M., et al. Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. J Vasc Surg 24 (1996) 513-521
54. Comerota A.J., Weaver F.A., Hosking J.D., et al. Results of prospective, randomized trial of surgery versus thrombolysis for occluded lower extremity bypass grafts. Am J Surg 172 (1996) 105-112
55. Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of limb peripheral arterial occlusion: a consensus document. Am J Cardiol 81 (1998) 207-218